A Clinical Study of MK-1084 With Rosuvastatin and Metformin in Healthy People (MK-1084-016)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: MK-1084; Drug: Metformin; Drug: Rosuvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT07222098

MK-1084-016 (Other Identifier)

1084-016

Details and patient eligibility

About

Researchers want to learn about MK-1084 when given with rosuvastatin and metformin in healthy people. The goal of this study is to compare the amount of rosuvastatin and metformin in a person's body over time when given with and without MK-1084

Enrollment: 16 patients

Sex: All

Ages: 19 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

- Has body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m^2

Exclusion criteria

The main exclusion criteria include but are not limited to the following:

• Has history of cancer (malignancy)
• Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

16 participants in 2 patient groups

Rosuvastatin + metformin

Experimental group

Description:

Participants will receive rosuvastatin plus metformin

Treatment:

Drug: Rosuvastatin

Drug: Metformin

Rosuvastatin + metformin + MK-1084

Experimental group

Description:

Participants will receive rosuvastatin plus metformin plus MK-1084

Treatment:

Drug: Rosuvastatin

Drug: Metformin

Drug: MK-1084